EP3621643A4 - Anti-malaria-antikörper, die das circumsporozoit-protein binden - Google Patents

Anti-malaria-antikörper, die das circumsporozoit-protein binden Download PDF

Info

Publication number
EP3621643A4
EP3621643A4 EP18798204.6A EP18798204A EP3621643A4 EP 3621643 A4 EP3621643 A4 EP 3621643A4 EP 18798204 A EP18798204 A EP 18798204A EP 3621643 A4 EP3621643 A4 EP 3621643A4
Authority
EP
European Patent Office
Prior art keywords
bind
circumsporozoite protein
malarial antibodies
malarial
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18798204.6A
Other languages
English (en)
French (fr)
Other versions
EP3621643A1 (de
Inventor
Qi LIANG
Sean Matthew CARROLL
Daniel Eric EMERLING
Allan Bradley
Paul Kellam
pela BINTER
Simon James Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Atreca Inc
Original Assignee
Kymab Ltd
Atreca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd, Atreca Inc filed Critical Kymab Ltd
Publication of EP3621643A1 publication Critical patent/EP3621643A1/de
Publication of EP3621643A4 publication Critical patent/EP3621643A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18798204.6A 2017-05-11 2018-05-11 Anti-malaria-antikörper, die das circumsporozoit-protein binden Pending EP3621643A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762504863P 2017-05-11 2017-05-11
US201762560971P 2017-09-20 2017-09-20
US201762564066P 2017-09-27 2017-09-27
PCT/US2018/032366 WO2018209265A1 (en) 2017-05-11 2018-05-11 Anti-malarial antibodies that bind circumsporozoite protein

Publications (2)

Publication Number Publication Date
EP3621643A1 EP3621643A1 (de) 2020-03-18
EP3621643A4 true EP3621643A4 (de) 2021-07-21

Family

ID=64105059

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18798204.6A Pending EP3621643A4 (de) 2017-05-11 2018-05-11 Anti-malaria-antikörper, die das circumsporozoit-protein binden

Country Status (2)

Country Link
EP (1) EP3621643A4 (de)
WO (1) WO2018209265A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
SI3723858T1 (sl) 2018-12-21 2022-04-29 Kymab Limited Bispecifično protitelo FIXAXFX s skupno lahko verigo
EP3962523A2 (de) * 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralisierende antikörper gegen das plasmodium-falciparum-circumsporozoit-protein und verwendung davon
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
EP3994166A1 (de) * 2019-07-01 2022-05-11 Deutsches Krebsforschungszentrum Plasmodiumantikörper

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028644A1 (en) * 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
WO2017163049A1 (en) * 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20160298072A1 (en) * 2013-11-20 2016-10-13 Cmc Biologics A/S A bioreactor system and method for producing a biopol ymer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028644A1 (en) * 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
WO2017163049A1 (en) * 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRAIG PRZYSIECKI ET AL: "Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex", FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, vol. 2, 1 January 2012 (2012-01-01), pages 1 - 11, XP055375838, DOI: 10.3389/fcimb.2012.00146 *
ROBERTO ANKER ET AL: "VH and VL region structure of antibodies that recognize the (NANP)s dodecapeptide sequence in the circumsporozoite protein of Plasmodium falciparum", EUR. J. IMMUNOL, vol. 20, 1 January 1990 (1990-01-01), pages 2757 - 2761, XP055374618, DOI: 10.1002/eji.1830201233 *
See also references of WO2018209265A1 *

Also Published As

Publication number Publication date
WO2018209265A1 (en) 2018-11-15
EP3621643A1 (de) 2020-03-18

Similar Documents

Publication Publication Date Title
EP3589313A4 (de) Anti-tigit-antikörper
IL260846B (en) Antigen binding proteins that bind pd-l1
EP3481869A4 (de) Anti-cd73-antikörper
EP3498840A4 (de) Anti-lag-3-antikörper
EP3325009A4 (de) Antikörpertherapeutika zur bindung von lag3
EP3334757A4 (de) Anti-tigit-antikörper
EP3256165A4 (de) Antikörpertherapeutika mit bindung von ctla4
EP3297671A4 (de) Anti-ror1-antikörper
EP3354729A4 (de) Anti-garp-antikörper
EP3265125A4 (de) Antikörpertherapeutika mit bindung von cd47
EP3661558A4 (de) Anti-il1rap-antikörper
EP3606961B8 (de) Garp-tgf-beta-antikörper
EP3621643A4 (de) Anti-malaria-antikörper, die das circumsporozoit-protein binden
EP3492591A4 (de) Anti-b7-h4-antikörper
EP3252074A4 (de) Anti-alk2-antikörper
EP3183001A4 (de) Antigenbindende proteine zur bindung von cxcr5
EP3581587A4 (de) Gerinnungshemmender faktor-xi-antikörper
EP3691447A4 (de) Anti-transthyretin-antikörper
EP3349794A4 (de) Anti-cd115-antikörper
EP3526247A4 (de) Anti-il1-rap-antikörper
EP3563868A4 (de) Pharmazeutisches präparat, das monoklonale cd147-antikörper stabil enthält
EP3526251A4 (de) Anti-p53-antikörper
EP3266872A4 (de) Neuartiger anti-pad4-antikörper
EP3297662A4 (de) An axl-proteine bindende antikörper
EP3381941A4 (de) Anti-epha4-antikörper

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WATSON, SIMON JAMES

Inventor name: LIANG, QI

Inventor name: EMERLING, DANIEL ERIC

Inventor name: CARROLL, SEAN MATTHEW

Inventor name: KELLAM, PAUL

Inventor name: BRADLEY, ALLAN

Inventor name: BINTER, PELA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KYMAB LIMITED

Owner name: ATRECA, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210618

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/015 20060101AFI20210614BHEP

Ipc: C07K 14/445 20060101ALI20210614BHEP

Ipc: C12N 15/09 20060101ALI20210614BHEP

Ipc: C12N 1/21 20060101ALI20210614BHEP

Ipc: C07K 16/20 20060101ALI20210614BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KYMAB LIMITED

Owner name: ATRECA, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230807

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240508